Compare Dollar Tree, Inc. (DLTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs TG Therapeutics Inc — how do they compare? Dollar Tree, Inc. trades at $118.58 (market cap $22.26B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Dollar Tree, Inc. is far larger — about 2.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and TG Therapeutics Inc for 16 Days on average.
| DLTR | TGTX | |
|---|---|---|
Market Cap | $22.26B | $8.16B |
Volume | 2,317,428 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $59.06 |
52-Week Low | $86.80 | $26.94 |
Typical Hold Time | 58 Days | 16 Days |
Enterprise Value | $28.87B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.64, up 2.01% with bullish technical signals and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 14.54, ROE of 45.87%, and positive cash flow trends. Recent news highlights strategic initiatives and institutional buying interest, though margin pressures and tariff volatility remain concerns.
DLTR presents a compelling investment case with improving earnings outlook and attractive valuation metrics. However, investors should weigh the strong analyst consensus (53% buy ratings, $139.33 target) against margin risks and recent insider selling activity that could signal near-term headwinds.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
